• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunic Inc (NQ: IMUX )

    1.145 -0.005 (-0.43%)
    Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 88,495
    Open 1.140
    Bid (Size) 1.110 (5)
    Ask (Size) 1.150 (10)
    Prev. Close 1.150
    Today's Range 1.110 - 1.160
    52wk Range 0.9451 - 3.110
    Shares Outstanding 26,249,439
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying
    While speculative ideas are treacherous, you can possibly reduce your blood pressure with these penny stocks with insider buying. 
    Via InvestorPlace
    Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
    Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20. 
    Via TheNewswire.com

    Performance

    YTD
    -21.03%
    -21.03%
    1 Month
    -9.84%
    -9.84%
    3 Month
    -6.15%
    -6.15%
    6 Month
    -19.93%
    -19.93%
    1 Year
    -60.10%
    -60.10%

    More News

    Read More
    Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
    Via News Direct
    Immunic chief medical officer discusses promising treatments to mark World IBD Day
    Via News Direct
    Immunic chief medical officer discusses promising treatments to mark World IBD Day
    Via TheNewswire.com
    IMUX Stock Earnings: Immunic Misses EPS for Q1 2024
    Via InvestorPlace
    Immunic's Earnings Outlook
    Via Benzinga
    Immunic: Q3 Earnings Insights
    Via Benzinga
    A Preview Of Immunic's Earnings
    Via Benzinga
    Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
    Via News Direct
    Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
    Via TheNewswire.com
    Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
    Via News Direct
    Topics Intellectual Property
    Exposures Intellectual Property
    Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
    Via TheNewswire.com
    Topics Intellectual Property
    Exposures Intellectual Property
    Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
    Via News Direct
    Immunic "super excited" about latest PMS trial data
    Via News Direct
    Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
    Via TheNewswire.com
    Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
    Via News Direct
    Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
    Via TheNewswire.com
    Immunic And 2 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What's Going On With Immunic Stock?
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Immunic CSO hails "great" progress with MS program
    Via News Direct
    Immunic CSO hails "great" progress with MS program
    Via TheNewswire.com
    Immunic "super excited" about latest PMS trial data
    Via TheNewswire.com
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.